Remimazolam is an ultrashort-acting benzodiazepine intravenous anesthetic that has recently been released. When using the total intravenous anesthesia technique, electroencephalogram（ECG）monitoring is recommended to maintain adequate depth of sedation. However, ECG during the administration of remimazolam sometimes differs from that of the previously standardized propofol in that beta waves are more likely to be observed, Burst Suppression is less likely to be detected, while higher processed ECG values are likely to be calculated. These factors make ECG monitoring challenging to interpret, so the condition of the patient must be comprehensively monitored when remimazolam is used.